Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?
Rossert
Jerome
J
McClellan
William M
WM
Roger
Simon D
SD
Verbeelen
Dierik L
DL
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D017209:Apoptosis; D004921:Erythropoietin / Q000627:therapeutic use*; D005355:Fibrosis; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007684:Kidney Tubules / Q000473:pathology; D008954:Models, Biological; D018384:Oxidative Stress; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin